FDA grants IDE nod to LensGen’s presbyopia-correcting intraocular lens

[Image from LensGen]Intraocular lens developer LensGen announced today that it received FDA investigational device exemption (IDE) for its Juvene lens.

Irvine, California-based LensGen designed the Juvene intraocular lens (IOL) for patients with cataracts, with the IDE set to initiate a pivotal study for the device.

The company developed Juvene IOL t0 permanently restore clear and continuous vision at all distances, including near and immediate. The lens is modular and has a fluid optic component designed to change shape to adjust focus on demand for active lifestyles.

Additionally, the lens offers improved viewing for mobile devices and computer screens, as well as distance vision in a wide range of lighting conditions. LensGen said that the lens is implanted using the same surgical techniques as with traditional IOL devices.

LensGen noted that it is currently in the process of raising a Series B financing round, with expectations of closing that …

Read more
  • 0

LensGen closes $10 million in bridge financing

LensGen’s Juvene IOL (Image from LensGen)

Intraocular lens developer LensGen announced today that it closed the addition of $10 million in a $20 million bridge financing.

HOYA Group’s corporate investment arm led the financing, which is part of a larger Series B round planned for early 2021 that is earmarked for funding the company through the approval of a pivotal FDA study for its Juvene fluid-optic intraocular lens (IOL) for cataract and presbyopia treatment, according to a news release.

“We are delighted to attract additional investment from an experienced ophthalmology and corporate strategic investor like HOYA in order to advance into the pivotal stage of our FDA clinical study and bring to market an innovative and elegant solution for treating cataracts and presbyopia,” LensGen founder & CEO Ramgopal Rao said in the release.

Irvine, Calif.-based LensGen also a…

Read more
  • 0